Objectives To assess the risks of and factors associated with mortality, loss to follow-up, and changing regimens after children with HIV infected perinatally initiate combination antiretroviral therapy (cART) in Latin America and the Caribbean.
increased estimated number of persons living with HIV, from 1.60 million in 2000 to 1.75 million in 2012, of whom 56 000 are children. 8 Rates of mortality after initiating cART have been studied for Latin American adults, 9, 10 but no study has yet characterized mortality rates among children starting cART in multiple cohorts in the region. We sought to estimate rates of mortality for children during the first year and beyond on cART and to assess predictors of mortality and determinants of initial regimen change among children in the Caribbean and Central and South America.
Methods
The Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet) has been described elsewhere. 11 To summarize, CCASAnet is a consortium of HIV clinics in Latin America and Haiti, 1 of 7 global regions affiliated with the International Epidemiologic Databases to Evaluate AIDS network supported by the US National Institutes of Health. Six clinics providing pediatric care contributed data to this study: Hospital Fernandez, Buenos Aires, Argentina; Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Universidade Federal de São Paulo, São Paulo, Brazil; Le Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, Port-auPrince, Haiti; and Hospital Escuela Universitario and Instituto Hondureño de Seguridad Social, Tegucigalpa, Honduras. Deidentified data were sent to the CCASAnet Data Coordinating Center at Vanderbilt University, Nashville, Tennessee, for data harmonization, quality checks, and analysis. The CCASAnet Data Coordinating Center at Vanderbilt University checked data for internal consistency. Institutional ethics review boards at each of the study sites and Vanderbilt University approved this study and waived the need for informed consent.
The study included ART-naïve, children with HIV who were infected perinatally and started cART when they were younger than 18 years of age, after clinic enrollment, and between 1997 and 2013. ART exposure as part of prevention of mother-tochild transmission (PMTCT) programs was not considered ART. Patients whose mode of infection was missing or unknown but who were diagnosed with HIV by the age of 10 years also were included. Most children were referred in by other clinics when HIV diagnosis was suspected/established. On average, less than one-quarter of children were enrolled in clinic who were younger than 1 year of age.
In this analysis, patients were followed from the date of cART initiation (baseline) to death or last visit. Children were considered lost to follow-up (LTFU) when their most recent visit was more than 12 months before the cohort database closing date, determined by the most recent visit in the cohort database. Absolute CD4+ T lymphocyte count (CD4 count) and CD4 percent at cART initiation were defined by the use of the measurements closest to cART initiation within a window of 180 days before and 7 days after. For those sites that routinely measure plasma HIV-1 RNA, the closest measurement to the date of cART initiation within a window of 180 days before and 0 days after was chosen.
Clinical stage before cART initiation of was categorized as AIDS or not AIDS; clinical AIDS was defined as US Centers for Disease Control and Prevention stage C, World Health Organization stage IV, or a specification of an AIDS diagnosis at the child's first visit.
Study outcomes were all-cause mortality, LTFU, and change of cART regimen. cART was defined as protease inhibitor (PI)-based (1 ritonavir-boosted or unboosted PI plus 2 nucleoside reverse transcriptase inhibitors [NRTI]), non-nucleoside reverse transcriptase inhibitor (NNRTI)-based (1 NNRTI plus 2 NRTIs), or other combinations (including triple NRTI regimens and all other regimens containing at least 3 drugs). A regimen change was defined as a single drug change outside of the regimen class, a switch of 2 or more antiretrovirals in the initial cART regimen, or the addition of 2 or more antiretrovirals from the initial cART regimen. A regimen change also included deleting 1 or more antiretrovirals from the initial cART regimen so that the new regimen no longer met the definition of cART.
The cumulative incidence of death was estimated via the use of Kaplan-Meier methods. The cumulative incidences of regimen change and LTFU were estimated treating death as a competing event. Cox proportional hazards models were stratified by site and used to examine with cause-specific hazard ratios (HRs) the association between predictors and the times to death, LTFU, or changing regimens. Predictors of interest that were included in the models were age, sex, CD4 count at cART initiation (square root transformed), year of cART initiation, first cART regimen class (including a PI, or not including a PI), and clinical AIDS. Continuous predictors were included in the models by the use of restricted cubic splines with predictors expanded by the use of 4 knots placed at default locations (5th, 35th, 65th, and 95th quantiles). HRs for continuous variables were presented by comparing the predicted hazards at specific prespecified levels vs reference levels (eg, CD4 = 200 cells/mm 3 vs CD4 = 350 cells/ mm 3 ). Missing CD4 counts (n = 118; 10% of patients) were multiply imputed 10 times using the R function aregImpute, which uses additive regression, bootstrapping, and predictive mean matching, 12 and then incorporated into analyses via a standard multiple imputation techniques. 13 To verify the fit of our imputation models, in the subset of patients with nonmissing CD4 count, we compared the mean difference between imputed CD4 (pretending CD4 was unavailable) and observed CD4; the mean difference for the 10 imputation replications varied from −40 to 37 cells/mm 3 , which represent −0.06 to 0.06 SDs from zero, suggesting the imputation was adequate. CD4 percent is the preferred measure of disease progression in subjects younger than 5 years of age rather than CD4 count; however, not all sites recorded this information. Therefore, secondary analyses were performed for children younger than 5 in the subset of sites that recorded CD4 percent.
All analyses were performed with R statistical software (The R Project for Statistical Computing, Vienna, Austria Table I shows characteristics of children starting cART by site. Approximately one-half of the children (614; 52.3%) started cART when they were younger than age of 5 years; the median (IQR) age for cART initiation was 4.7 years (1.7-8.8 years). The median age at HIV diagnosis was 3.3 years (IQR 1.0-7.0); date of HIV diagnosis was missing for 26 (2%) children. More than one-half (53%) were female, and the median year of cART initiation was 2005 (IQR 2003 (IQR -2009 range 1997 . Median age at cART initiation tended to increase with calendar year up until 2007-2008, after which it decreased, although patterns varied by site (Figure 1 ; available at www.jpeds.com). Time from enrollment to cART initiation varied substantially by site, but the overall median was 3.4 months (IQR 1.1-14.1). At initiation of cART, 36% of children had clinical AIDS, 60% did not, and 4% had an unknown clinical AIDS status. The median CD4 count at cART initiation was 472 cells/mm 3 (IQR 201-902); for children 5 years or older, and the median CD4 count was 294 (IQR 114-494). For children younger than 5, the median CD4 percent at cART initiation was 19% (IQR [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] in the subset for whom CD4 percent was available (60%). A PI-based regimen was initiated for 19% of children (29% of children younger than 5 years and 8% if 5 years or older), although greater than 50% initiated PI-based regimens at the sites in Argentina and Brazil, whereas less than 10% initiated PI-based regimens at the sites in Haiti and Honduras. Lopinavir/ ritonavir (n = 59) and nelfinavir (n = 41) were the most common PIs used.
Median follow-up was 5.6 years (IQR 2.3-9.3); follow-up was similar across age groups (eg, median of 5.8 and 5.4 years for those younger than 5 and 5 years or older at cART initiation, respectively). Twelve percent (n = 138) of patients died during follow-up, and 21% were LTFU.
The cumulative incidence of death and LTFU after cART initiation are shown in left and middle panels of Figure 2 , respectively. The probability of death was high, 0.06 (95% CI 0.04-0.07), in the first year of cART. The cumulative incidence of mortality 5 years after cART initiation was 0.12 (95% CI 0.10-0.14). The cumulative incidence of LTFU at 1 and 5 years was 0.06 (95% CI 0.04-0.07) and 0.16 (95% CI 0.14-0.18), respectively. Table II shows the associations between patient characteristics at cART initiation and mortality, stratified by study site and with adjustment for all other variables. Age was a strong predictor of mortality across the entire cohort (P < .001), with younger children starting ART generally having a greater risk of mortality than older children. For example, after we controlled for sex, CD4 count, year of first cART, first cART regimen class, clinical status, and study site, a child who initiated cART at the age of 6 months had an estimated hazard of death that was 2.6 times greater than that of a child starting at the age of 5 years (95% CI 1.6-4.2); however, there was some weaker evidence suggesting that the risk of mortality also was greater for adolescents (eg, P value for nonlinearity was .001; adjusted HR comparing age 15 years with age 5 years was 1.33, 95% CI 0.74-2.41). The left panel of Figure 3 shows the predicted 5-year probability of mortality as a function of age, when all other factors are constant. Baseline CD4 count also was a strong predictor of mortality, with those having lower CD4 counts at cART initiation having greater hazards of death. Similarly, children with a clinical diagnosis of AIDS at baseline had almost twice the hazard of death as those who did not (HR 1.9, 95% CI 1.3-2.7). Year of cART initiation was not a strong predictor of mortality after we controlled for other variables. Results were similar when the analysis was restricted to those sites that collected CD4 percent. Among children younger than 5 years at cART initiation, those with CD4 percent of 10 had a hazard of mortality 1.75 times greater than those with CD4 percent of 25 (95% CI 1.1-2.7). Table II also shows the associations between patient characteristics at cART initiation and being LTFU, stratified by site and controlling for all other variables. Age was the strongest predictor of LTFU (P < .001). For example, after we adjusted for other variables, the hazard of being LTFU was 2.23 times greater for children 15 years old than for children 5 years old. The estimated probability of being LTFU as a function of age is shown in middle panel of Figure 3 .
A total of 370 children (32%) changed regimens during follow-up; 28 removed 1 or more antiretroviral and the remaining 342 switched/added 2 or more drugs and/or made a single out-of-class drug substitution. Of the 370 children who changed regimens, 198 (54%) had failure/nonadherence listed as the reported reason for change (treatment failure [111], virologic failure [57], nonadherence [20] , drug resistance based on HIV genotype [8] , immunologic failure [1] , and clinical progression [1] ). Toxicity was the reported reason for change for 49 (13%) patients, with abdomen/gastrointestinal toxicities being the most common (n = 14). Other reported reasons for changing regimens included TB treatment drug interaction (n = 20), drugs not available (n = 16), more effective or simplified treatment available (n = 11), unspecified patient or physician decisions (n = 16), or unspecified other reasons (n = 24). Reason for changing regimen was unknown for 36 (10%) patients. The most common regimens changed were lamivudine + zidovudine + efavirenz (n = 98), didanosine + zidovudine + nelfinavir (n = 51), lamivudine + zidovudine + nevirapine (n = 34), didanosine + zidovudine + efavirenz (n = 33), and lamivudine + zidovudine + nelfinavir (n = 30).
The right panel of Figure 2 illustrates the cumulative incidence of regimen change with death treated as a competing risk. The 1-and 5-year incidences of regimen change were 0.08 (95% CI 0.06-0.09) and 0.29 (95% CI 0.26-0.32), respectively. Table II shows the associations between patient characteristics at cART initiation and regimen change, stratified by study site and controlling for all other variables. Older age at cART initiation was associated with a greater hazard of changing regimens (P = .008). For example, the hazard of regimen change for a 15-year-old patient starting cART was 1.71 times greater (95% CI 1.14-2.56) than for a 5-year-old patient starting cART, after we controlled for other factors. The right panel of Figure 3 shows the predicted probability of changing regimens as a function of age. Year of cART initiation and class of first cART also were strong predictors of regimen change in adjusted analyses (P < .01). Greater hazards of regimen change were associated with earlier years of cART initiation (HR 1.30; 95% CI 1.07-1.58 for those who initiated cART in 2002 compared with 2006). In addition, non-PI regimens had lower hazards of regimen change compared with PI-based regimen (HR 0.47; 95% CI 0.34-0.66). In addition, lower baseline CD4 count was associated strongly with regimen change (HR 1.29; 95% CI 1.13-1.48 for CD4 counts of 100 compared with 350 cells/mm 3 ).
Discussion
Treatment outcomes of children with HIV on initial cART in the Caribbean and Central and South America were disappointing. The majority of children initiated a NNRTI-based regimen at advanced stages of disease progression and immunosuppression. Risk of mortality during the first 5 years of treatment was significant. Mortality also tended to be greater among younger children (ie, younger than 5 years), although there was some evidence suggesting that adolescents also were at greater risk. These findings are similar to those reported in a systematic review of 30 pediatric ART programs in sub-Saharan Africa, 14 reflecting, perhaps, that pediatric HIV programs in the Americas face some of the same challenges seen in African programs, including failures in PMTCT, and among infants with HIV, late diagnosis and initiation of cART and high subsequent LTFU.
At 5 years of treatment, approximately 70% of participants remained on initial cART regimens. The incidence of changing regimens tended to be greater for older children. The durability of the first-line regimen in our study is comparable with what has been reported for pediatric populations in both high-and low-income settings, [15] [16] [17] emphasizing good responses to first-line cART in children regardless of type of regimen and initiation at later stages of disease. NNRTIbased cART had lower risks of change than PI-based regimens in our children.
Regimen change rates decreased over calendar time in children starting ART in the Caribbean and Central and South America. Possible reasons include more tolerable and effective drugs, improved pediatric formulations, earlier initiation of treatment, better management of HIV and comorbidities, and better adherence over time. Changes in national and international pediatric treatment guidelines during the study period also may have influenced this finding, especially after 2009-2010, when programs adopted universal treatment to infants and greater CD4 thresholds for cART initiation. The parabolic shape of the predicted incidence of mortality as a function of age, with those starting cART between ages 5 and 10 years having the lowest risk of death, may have several explanations. The youngest children placed on cART may have been initiated due to rapid clinical deterioration, such that they were systematically different from the comparatively healthier children placed on cART at a later age. In addition, if younger aged children died of serious childhood diseases without being diagnosed with HIV and/or placed on cART, then they would be absent from the older cohort; this would be a second reason why older children might be less likely to include the rapid progressors that were included in the younger cohort. 18 There are very few data on the experience of pediatric patients starting cART in Latin America and the Caribbean. Our observed risks of mortality for very young children with HIV are substantially lower than those estimated via use of the HIV Paediatric Prognostic Markers Collaborative Study risk calculator, which was derived with data in the absence of cART in US and European cohorts. 19 For example, the 1-year predicted probability of mortality for a child diagnosed with HIV at 1 year of age with CD4 = 200 cells/mm 3 was 0.38 when the risk calculator was used, whereas this predicted probability in our Latin American cohort of cART initiators (holding all other covariates at their medians/modes) was 0.16. The observed risk of mortality for older children starting cART in our cohort, however, was substantially greater than predicted by the risk calculator in the absence of cART in the developed world. For example, the 1-year predicted probability of mortality for a child diagnosed with HIV at the age of 10 years with CD4 = 200 cells/ mm 3 was 0.01 when the risk calculator was used, whereas it was 0.07 based on our data. Although such comparisons are flawed, they perhaps help illustrate both the successes and challenges for perinatally infected children in Latin America during the cART era.
That one-half of the children in the cohorts started cART when they were older than the age of 5 years is a concern for PMTCT programs in the Americas. Authors of the Children with HIV Early Antiretroviral Therapy (CHER) study demonstrated the superiority of immediate cART over delayed treatment for infected infants. 20 Yet, therapy for infants younger than the age of 3 months was the exception in our 6 clinic cohorts, not the rule. Infants born with HIV infection indicates suboptimal functioning of the clinical and public health PMTCT paradigm.
LTFU was greater for older children and actually seemed to accelerate after longer times on treatment for older children. This result may be a reflection of the challenges of retaining adolescents in care. 21 It is also possible that there was "treatment fatigue" and that parents or guardians stopped therapy in apparently healthy children with HIV. The literature for Latin America and the Caribbean suggests many causes for nonadherence, primarily among adults: stigma, access to care, denial, drug side effects, lack of appreciation that drugs can help persons who are asymptomatic, depression, substance use, inattentive parenting, illness or death of a mother, health system disarray, poverty, transportation, and others. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] It is also plausible that over time children's families moved and the children either went off of therapy or entered into ART programs elsewhere and this was not captured in our cohorts. 15 Study strengths include the inclusion of diverse cohorts from 6 venues in Argentina, Brazil (2 sites), Haiti, and Honduras (2 sites), the inclusion of 1174 children, and our strong statistical methods to maximize the utility of clinical data. Limitations of our study include missing data in our real-world settings, small numbers of children (13 and 17) from 2 of the 6 sites, and a lack of detail as to why some children were LTFU. Data on cause of death also were unavailable, as were maternal information (eg, mother's age, duration of HIV infection, and clinical outcomes) and population genetics data. Expanding the utility of clinical databases to include social determinants and to link maternal and pediatric databases are goals of our CCASAnet network, as well as improving the quality and completeness of data collection. 36, 37 Our study from diverse cohorts in Argentina, Brazil, Haiti, and Honduras suggests the urgency of need for quality improvement for PMTCT, maternal and child HIV programs, and early pediatric care in Latin America and the Caribbean. Our challenges are not unique and are experienced in both highand low-income settings. 38, 39 The management of a chronic, lifelong, incurable infectious disease in the context of stigma and poverty is challenging for parents and practitioners alike; innovative approaches are needed in the Americas and the Caribbean. 
